NASDAQ$PIII
P3 Health Partners Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
P3 Health's financial performance increased in revenue but decreased in profitability during the second quarter of 2024.
P3 Health Partners reported a revenue increase of 15% compared to the prior year, driven by growth in capitated revenue. However, gross profit and medical margin decreased, leading to a net loss. The company is focusing on initiatives to enhance capabilities and achieve sustainable profitability.
- Total revenue increased by 15% to $379.2 million compared to the second quarter of the prior year.
- Capitated revenue increased by 15% to $374.3 million compared to the second quarter of the prior year.
- Gross profit was $14.0 million, compared to $26.8 million in the prior year.
- Net loss was $28.8 million, compared to a net loss of $27.6 million in the second quarter of the prior year.
Headline financials
Revenue & EPS history
P3 Health · Revenue · Quarterly
$379M
Revenue by segment
P3 Health · $386M total across 2 segments · Q1 2026
- Capitated Revenue$379M—98.2%
- Other Revenue$6.89M—1.8%
Forward guidance
P3 Health Partners provided financial guidance for the year ending December 31, 2024.
Tailwinds
- Total Revenues (in millions): $1,450 - $1,550
- Medical margin (in millions): $230 - $250
- Medical margin PMPM: $165 - $175
- Adjusted EBITDA (in millions): $20 - $40
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2024
-3.8%
Avg return
Earnings day
+2.0%
Avg return
5 days after
-15.6%
Avg return
30 days after
37%
7 / 19 earnings
Positive
+11.2%
Q1 2026
Best reaction
-36.8%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +11.2% | +194.4% | — | |
| Q4 2026 | +0.7% | -1.8% | -5.4% | |
| Q3 2025 | +0.4% | -12.6% | -25.9% | |
| Q2 2025 | -2.5% | +5.4% | +23.9% | |
| Q1 2025 | -0.6% | -5.9% | -19.5% | |
| Q4 2024 | -4.5% | +1.1% | -1.2% | |
| Q3 2024 | -36.8% | -42.2% | -46.0% | |
| Q2 2024 | -2.5% | -8.7% | -24.1% | |
| Q1 2024 | +2.6% | -11.8% | -21.6% | |
| Q4 2023 | -13.3% | -22.4% | -56.3% | |
| Q4 2021 | +3.1% | -7.6% | -12.2% | |
| Q3 2023 | -2.1% | -8.8% | -19.0% | |
| Q2 2023 | +0.9% | -10.8% | -5.0% | |
| Q4 2022 | -5.9% | -12.7% | +15.5% | |
| Q3 2022 | -11.8% | -19.7% | -33.5% | |
| Q1 2022 | -5.9% | +2.1% | -16.8% | |
| Q2 2022 | -4.1% | +0.6% | -14.0% | |
| Q3 2021 | +0.1% | +0.3% | -19.9% | |
| Q2 2021 | -0.7% | -0.2% | +0.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro